The Top 5 Biosimilars Articles for the Week of September 23

The Center for Biosimilars® recaps the top stories for the week of September 23, 2019.


Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of September 23, 2019.

Number 5: Generium has received approval for the first biosimilar dornase alfa, which treats cystic fibrosis, in Russia.

Number 4: A newly published paper concludes that, as experience and analytical capabilities mature, there will be a reduced requirement for clinical data in biosimilar development.

Number 3: Two biosimilar bills, both with bipartisan sponsors, were unveiled last week.

Number 2: The Committee for Medicinal Products for Human Use issued a positive opinion for Celltrion’s subcutaneously administered biosimilar infliximab for the treatment of rheumatoid arthritis.

Number 1: The FDA has released a new suite of resources to educate patients about biosimilars.

Finally, last week, our e-newsletter asked whether you think that the 2020 launch of authorized generics of 2 of Novo Nordisk’s insulin products will help patients afford their medication.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit

Related Videos
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Ian Henshaw
John Gabrielson
Nabil Saba
Ryan Haumschild, PharmD
Julie M. Reed
Gillian Woollett, MA, Dphil
Julie M. Reed
Related Content
© 2023 MJH Life Sciences

All rights reserved.